JP2023516291A5 - - Google Patents
Info
- Publication number
- JP2023516291A5 JP2023516291A5 JP2022551377A JP2022551377A JP2023516291A5 JP 2023516291 A5 JP2023516291 A5 JP 2023516291A5 JP 2022551377 A JP2022551377 A JP 2022551377A JP 2022551377 A JP2022551377 A JP 2022551377A JP 2023516291 A5 JP2023516291 A5 JP 2023516291A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- pharmaceutical composition
- inhibitor
- composition according
- estrogen receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025090731A JP2025131656A (ja) | 2020-03-06 | 2025-05-30 | エストロゲン受容体関連疾患の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062985929P | 2020-03-06 | 2020-03-06 | |
| US62/985,929 | 2020-03-06 | ||
| PCT/US2021/021151 WO2021178846A1 (en) | 2020-03-06 | 2021-03-05 | Methods of treating estrogen receptor-associated diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025090731A Division JP2025131656A (ja) | 2020-03-06 | 2025-05-30 | エストロゲン受容体関連疾患の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023516291A JP2023516291A (ja) | 2023-04-19 |
| JP2023516291A5 true JP2023516291A5 (enExample) | 2024-03-14 |
| JP7708772B2 JP7708772B2 (ja) | 2025-07-15 |
Family
ID=77613854
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551377A Active JP7708772B2 (ja) | 2020-03-06 | 2021-03-05 | エストロゲン受容体関連疾患の治療方法 |
| JP2025090731A Pending JP2025131656A (ja) | 2020-03-06 | 2025-05-30 | エストロゲン受容体関連疾患の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025090731A Pending JP2025131656A (ja) | 2020-03-06 | 2025-05-30 | エストロゲン受容体関連疾患の治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230129598A1 (enExample) |
| EP (1) | EP4114391B1 (enExample) |
| JP (2) | JP7708772B2 (enExample) |
| KR (1) | KR20220151616A (enExample) |
| CN (1) | CN115175679A (enExample) |
| AU (1) | AU2021230588A1 (enExample) |
| CA (1) | CA3169679A1 (enExample) |
| ES (1) | ES3044433T3 (enExample) |
| MX (1) | MX2022010425A (enExample) |
| WO (1) | WO2021178846A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3847157T3 (da) | 2018-09-07 | 2022-08-08 | Sanofi Sa | Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf |
| CA3144791A1 (en) * | 2019-07-07 | 2021-01-14 | Olema Pharmaceuticals, Inc. | Regimens of estrogen receptor antagonists |
| WO2021063967A1 (en) | 2019-10-01 | 2021-04-08 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| CA3160897A1 (en) | 2019-12-09 | 2021-06-17 | Sanofi | Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative |
| TW202146007A (zh) * | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| IL302153B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| IL302152B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| EP4294395B1 (en) * | 2021-02-16 | 2025-03-26 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077 |
| TW202304425A (zh) * | 2021-04-12 | 2023-02-01 | 法商賽諾菲公司 | 包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合 |
| TW202304424A (zh) * | 2021-04-12 | 2023-02-01 | 法商賽諾菲公司 | 包含依維莫司和安森司群的組合 |
| TW202333704A (zh) * | 2021-11-12 | 2023-09-01 | 大陸商先聲藥業有限公司 | 用於治療腫瘤的藥物組合及其應用 |
| PE20241731A1 (es) * | 2022-02-01 | 2024-08-19 | Lilly Co Eli | Procesos para la preparacion de degradadores selectivos del receptor de estrogeno |
| WO2023150238A1 (en) * | 2022-02-02 | 2023-08-10 | Intrinsic Innovation Llc | Object placement |
| WO2023221123A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Crystalline forms of an estrogen receptor antagonist |
| WO2023221122A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Salts and solid forms of an estrogen receptor antagonist |
| WO2024015506A1 (en) * | 2022-07-14 | 2024-01-18 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
| CN114933558B (zh) * | 2022-07-26 | 2022-11-22 | 常熟药明康德新药开发有限公司 | 手性硝基化合物催化还原制备手性氨基化合物的方法 |
| CN120187424A (zh) * | 2022-10-05 | 2025-06-20 | 奥列马制药公司 | 治疗雌激素受体介导的病症的方法 |
| WO2024076633A1 (en) * | 2022-10-05 | 2024-04-11 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
| CN115872996B (zh) * | 2023-02-21 | 2023-05-05 | 山东绿叶制药有限公司 | 一种雌激素受体降解剂化合物及其制备方法和应用 |
| WO2025085738A1 (en) | 2023-10-18 | 2025-04-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| WO2025106890A1 (en) * | 2023-11-17 | 2025-05-22 | Olema Pharmaceuticals, Inc. | Salts and solid forms of an estrogen receptor antagonist |
| WO2025189056A1 (en) | 2024-03-08 | 2025-09-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010138659A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating brain tumors |
| CA2819299A1 (en) | 2010-12-24 | 2012-06-28 | Merck Sharp & Dohme B.V. | N-substituted azetidine derivatives |
| BR112014014767A2 (pt) | 2011-12-16 | 2017-06-13 | Olema Pharmaceuticals Inc | novos compostos de benzopirano, composições e usos dos mesmos |
| AP2015008858A0 (en) | 2013-05-28 | 2015-11-30 | Astrazeneca Ab | Chemical compounds |
| MA39740A (fr) * | 2014-03-13 | 2017-01-18 | Hoffmann La Roche | Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes |
| ES2939940T3 (es) * | 2014-03-28 | 2023-04-28 | Univ Duke | Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos |
| TWI784255B (zh) | 2014-12-18 | 2022-11-21 | 瑞士商赫孚孟拉羅股份公司 | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 |
| MX384605B (es) * | 2015-04-29 | 2025-03-14 | Radius Pharmaceuticals Inc | Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno. |
| WO2017059139A1 (en) * | 2015-10-01 | 2017-04-06 | Olema Pharmaceuticals, Inc. | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS |
| EP3585394A4 (en) | 2017-02-23 | 2021-06-30 | Olema Pharmaceuticals, Inc. | COMPOSITIONS AND PROCEDURES FOR REGULATING IMMUNE SYSTEM ACTIVITY |
| LT3810283T (lt) | 2018-06-21 | 2023-08-25 | F. Hoffmann-La Roche Ag | 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti |
| KR20210035211A (ko) * | 2018-07-23 | 2021-03-31 | 에프. 호프만-라 로슈 아게 | Pi3k 저해제인 gdc-0077로 암을 치료하는 방법 |
| AU2019321588C1 (en) * | 2018-08-17 | 2026-05-14 | Genentech, Inc. | Diagnostic and therapeutic methods for the treatment of breast cancer |
-
2021
- 2021-03-05 MX MX2022010425A patent/MX2022010425A/es unknown
- 2021-03-05 EP EP21763872.5A patent/EP4114391B1/en active Active
- 2021-03-05 CA CA3169679A patent/CA3169679A1/en active Pending
- 2021-03-05 US US17/908,941 patent/US20230129598A1/en active Pending
- 2021-03-05 ES ES21763872T patent/ES3044433T3/es active Active
- 2021-03-05 AU AU2021230588A patent/AU2021230588A1/en active Pending
- 2021-03-05 CN CN202180016388.2A patent/CN115175679A/zh active Pending
- 2021-03-05 KR KR1020227030151A patent/KR20220151616A/ko active Pending
- 2021-03-05 JP JP2022551377A patent/JP7708772B2/ja active Active
- 2021-03-05 WO PCT/US2021/021151 patent/WO2021178846A1/en not_active Ceased
-
2025
- 2025-05-30 JP JP2025090731A patent/JP2025131656A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101178318B1 (ko) | 효과적인 의약의 사용법 및 부작용 발현의 방어에 관한방법 | |
| JP6684210B2 (ja) | チロシン誘導体及びそれを含む組成物 | |
| JP2019056017A (ja) | Ｔｏｌｌ様受容体モジュレーターの固体形態 | |
| JP2022540421A5 (enExample) | ||
| JP2004507465A5 (enExample) | ||
| JP2019533670A5 (enExample) | ||
| EP3177311B1 (en) | Drug combinations of cabozantinib with proteasome inhibitor to treat multiple myeloma | |
| CN101378743A (zh) | 以2-氨基-1,3-丙二醇衍生物为有效成分的炎症性肠疾病治疗剂或炎症性肠疾病的治疗方法 | |
| JP2013501731A5 (enExample) | ||
| CN101360495B (zh) | 对癌症病人给药mTOR抑制剂 | |
| TW202333675A (zh) | 用於治療癌症之組合療法之用途 | |
| CN101277687B (zh) | 以2-氨基-1,3-丙二醇衍生物作为有效成分的肝脏疾病治疗剂及肝脏疾病治疗方法 | |
| TW202304424A (zh) | 包含依維莫司和安森司群的組合 | |
| JP2020523317A5 (enExample) | ||
| JP2023503167A5 (enExample) | ||
| EP3924351A1 (en) | Formulations comprising heterocyclic protein kinase inhibitors | |
| JP2019516726A5 (enExample) | ||
| CN112512516A (zh) | 用于在已经经历造血干细胞移植的患者中抑制血液恶性肿瘤复发的活性剂 | |
| JP2013525290A5 (enExample) | ||
| CN105616411A (zh) | 治疗结肠癌的组合物及其应用 | |
| WO2023178255A9 (en) | Combinations comprising metap2 inhibitors for the treatment of cancer | |
| JP2005512996A5 (enExample) | ||
| TWI709402B (zh) | 西達本胺與依西美坦在製備用於治療乳腺癌的聯合用藥物中的用途及聯合用藥物 | |
| JPH09506902A (ja) | 前立線癌の化学療法剤の補助剤 | |
| CN1505511A (zh) | 吡啶并吲哚酮类衍生物用于制备药物的用途 |